<- Go Home
Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.
Market Cap
$1.1B
Volume
220.3K
Cash and Equivalents
$100.6M
EBITDA
-$98.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$30.03
52 Week Low
$10.90
Dividend
N/A
Price / Book Value
3.55
Price / Earnings
-11.42
Price / Tangible Book Value
3.55
Enterprise Value
$767.5M
Enterprise Value / EBITDA
-7.82
Operating Income
-$99.1M
Return on Equity
30.98%
Return on Assets
-21.37
Cash and Short Term Investments
$291.8M
Debt
$85.0K
Equity
$288.4M
Revenue
N/A
Unlevered FCF
-$38.6M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium